ERR2278860
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.410
- MYC_TARGETS_V2+0.410
- OXIDATIVE_PHOSPHORYLATION+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- FATTY_ACID_METABOLISM+0.300
- MTORC1_SIGNALING+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.250
- DNA_REPAIR+0.220
- P53_PATHWAY+0.210
- E2F_TARGETS+0.190
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.470
- ANGIOGENESIS-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- UV_RESPONSE_DN-0.410
- INFLAMMATORY_RESPONSE-0.370
- MYOGENESIS-0.350
- TGF_BETA_SIGNALING-0.330
- HEDGEHOG_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278847 | — | — | 0.989 |
| 2 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.922 |
| 3 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.902 |
| 4 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.902 |
| 5 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.894 |
| 6 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.891 |
| 7 | SRR8518448 | — | C | 0.885 |
| 8 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.885 |
| 9 | SRR12475110 | — | — | 0.884 |
| 10 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |